TrustMF Small Cap Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of small cap companies. However, there is no assurance that the investment objective of the scheme will be realized.
Growthvine rating: 2/5 — ranked #25 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹13.50 (as of 2026-11-13) |
|---|
| AUM | ₹3,981 Cr |
|---|
| Expense ratio | 1.63% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Aakash Manghani |
|---|
| Exit load | 1% for redemption within 180 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −24.20% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 121.9% of NIFTY Smallcap 250's upside and 76.3% of its downside.
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 20.3% |
|---|
| Small cap | 79.7% |
|---|
Concentration
| Top 5 holdings | 12.9% |
|---|
| Top 10 holdings | 23.4% |
|---|
| Total holdings | 73 |
|---|
| Index overlap | 28.4% |
|---|
| Active share | 71.6% |
|---|
Top holdings
- TREPS 02-Nov-2026 — 4.6%
- Karur Vysya Bank Ltd. — 3.0%
- Laurus Labs Limited — 2.7%
- Ather Energy Limited — 2.6%
- Lenskart Solutions Limited — 2.4%
- ACUTAAS CHEMICALS LIMITED — 2.3%
- Multi Commodity Exchange of India Ltd — 2.2%
- City Union Bank Ltd — 2.2%
- PNB Housing Finance Limited — 2.1%
- Gland Pharma Limited — 2.0%
Top sectors
- Pharma & Biotech — 13.7%
- Industrial Products — 13.2%
- Banking & Financial — 11.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 26.3% | Q1 (Top) | #2 of 34 |
| 2025 | −0.7% | Q1 (Top) | #6 of 30 |